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Abstract Fungi cause opportunistic, nosocomial, and
community-acquired infections. Among fungal infections
(mycoses) zygomycoses are exceptionally severe, with a mor-
tality rate exceeding 50%. Immunocompromised hosts, trans-
plant recipients, and diabetic patients with uncontrolled keto-
acidosis and high iron serum levels are at risk. Zygomycota
are capable of infecting hosts immune to other filamentous
fungi. The infection often follows a progressive pattern, with
angioinvasion and metastases. Moreover, current antifungal
therapy frequently has an unfavorable outcome. Zygomycota
are resistant to some of the routinely used antifungals, among
them azoles (except posaconazole) and echinocandins. The
typical treatment consists of surgical debridement of the in-
fected tissues accompanied by amphotericin B administration.
The latter has strong nephrotoxic side effects, which make it
unsuitable for prophylaxis. Delayed administration of
amphotericin and excision of mycelium-containing tissues
worsens survival prognoses. More than 30 species of
Zygomycota are involved in human infections, among them
Mucorales is the most abundant. Prognosis and treatment
suggestions differ for each species, which makes fast and
reliable diagnosis essential. Serum sample PCR-based identi-
fication often gives false-negative results; culture-based iden-
tification is time-consuming and not always feasible. With the
dawn of Zygomycota sequencing projects significant ad-
vancement is expected, as in the case of treatment of Asco-
mycota infections.
Introduction
Zygomycota is an artificial grouping of distantly related basal
fungi. This term is broadly used for fungi belonging to
Mu c o r om y c o t i n a , E n t om o p h t h o r om y c o t i n a ,
Mo r t i e r e l l omyco t i n a , Zoop agomyco t i n a , a n d
Kickxellomycotina. The common name zygomycosis indi-
cates infections caused by organisms that diverged more than
800 MYA [1], preceding land colonization by plants. Conse-
quently, it should be broadly recognized that zygomycoses
have a variable prognosis depending on the causal agent and
patient’s condition. Mycology is undergoing a significant shift
toward molecular-based taxonomy, aiming at a more consis-
tent classification and nomenclature. A robust classification
reflecting biological similarities is of great significance for
medical purposes. The biochemical and physiological vari-
ability among fungal taxa lead to measurable effects, among
them antifungal resistance [2, 3]. Fast and accurate species (or
at least genus) recognition is essential for a successful treat-
ment in the case of less common fungi. Yet, in most laborato-
ries such in-depth classification is not routinely performed,
because these genera cannot be easily differentiated, for ex-
ample, histopathologically.
The broadly used and recognized term Zygomycota should
be abandoned in the future, in favor of proper taxonomic
names. Since the clinical manifestations and development of
infections with Mucorales and Entomophthorales are signifi-
cantly different, the name “zygomycosis” should also be
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abandoned in favor o f en tomoph tho romycos i s
(entomophthoromycosis), mortierellomycosis and
mucoralomycosis (mucormycosis). However, here, when de-
scribing the common features of many taxa, we will apply the
term Zygomycota. Emerging Zygomycota infections are be-
coming a serious threat at transplantation and on other wards
with immunocompromised patients. This phenomenon be-
come more pronounced after the introduction of serum-
based detection, diagnostic imaging, and modern antifungals
(voriconazole) that enabled efficient treatment of aspergillosis
[4]. Mucorales are the third most common agent of systemic
mycoses after invasive aspergillosis and candidiasis in hema-
tology patients [5]. This constantly growing group of suscep-
tible patients, together with improvements in the management
of invasive aspergillosis and candidiasis result in increased
interest in zygomycoses. In contrast to aspergillosis, most
cases of zygomycosis are fatal, despite the administration of
antifungal therapy [6–8]. The number of at-risk patients is
constantly growing, with the ubiquity of diabetes and immu-
nosuppressive treatment. Furthermore, Zygomycota are able
to colonize hosts not susceptible to other opportunistic fungal
infections, among them diabetic patients and intravenous drug
users [8]. In particular, representatives of the genus
Basidiobolus [9] and of the family Saksenaeaceae [10, 11]
have been reported to infect healthy hosts.
Here, we revise current knowledge on nomenclature, path-
ogenesis, and diagnostics of zygomycosis (mainly
mucormycosis).
Biology
Mucoromycotina representatives are ubiquitous organisms pres-
ent all over the world in the soil, infecting plants and other fungi
[12]. Importantly, the same species are found in clinical samples
and used in food fermentation. Entomophthoromycotina groups
more than 250 entomopathogenic, soil, and litter-associated
species [13]. Mortierellomycotina [14] harbor more than 100
taxa of saprotrophic soil organisms.
The knowledge on pathogenic Zygomycota ecology is very
limited and often anecdotal. Understanding the lifestyle of
pathogenic species is essential to understanding the epidemi-
ology and to formulating recommendations for at-risk pa-
tients. In medical mycology species from the order Mucorales
are the most common Zygomycota representatives.
Mucorales reproduce both sexually, by zygospores formed
after the fusion of hyphae of different mating types, and
asexually through sporangiospores produced within
sporangia. However, in most species zygospores production
is rarer and the conditions necessary for their formation and
germination remain unknown. In turn, asexual spores are
produced inmassive quantities and they can differ in character
[15]. Mucorales produce not only dry sporangiospores
dispersed by the air, but also wet sporangiospores, less prone
to aerosolization. Spore size and hydrophilic/hydrophobic
character impacts the dispersal of fungi. Zygomycetes that
infect humans are relatively hydrophilic, which limits every-
day exposure to their spores, even if they are ubiquitous in
spoiled food and their pathogenic strains do not differ from
environmental samples [16].
Even the most ubiquitous among Zygomycota (Rhizopus
and Mucor) are less common in air samples than the benign,
plant-associated Alternaria and Cladosporium [17, 18] in-
volved in human allergies. The prevalence of Mucorales
spores in dust and spoiled food compared with air samples is
consistent with the onset of infections after earthquakes and
massive inhalation of spores. Human pathogenic Ascomycota
are broadly encountered in air samples, whereas Zygomycota
are less abundant in air samples [19–21]. In liquid culture
Mucor circinelloides produces yeast cells; however, the role of
yeast forms in infection is unknown [22]. Furthermore,
M. circinelloides produces sporangiospores of different sizes
depending on the mating type variant [23]. The bigger
sporangiospores are able to lyse macrophages, which makes
them more virulent to a mammalian host.
Until recently, it was not clear whether the dimorphic
switch between aerobic hyphal growth and multi-budded
yeast growth under anaerobic/high CO2 conditions is related
to virulence in Mucorales. Lee and colleagues [24] showed
that a calcineurin inhibitor tacrolimus (FK506) prevents hy-
phal growth of Mucor spp. Furthermore, the cAMP-
dependent protein kinase A (PKA) is involved in the dimor-
phic transition as in other dimorphic fungi (Candida species,
Cryptococcus neoformans, Cryptococcus gattii, and Aspergil-
lus fumigatus). The yeast-locked mutants were less virulent
than wild-type strains, suggesting that hyphae are more viru-
lent or the dimorphic switch is important for the pathogenicity
of this fungus. Finally, the authors showed that calcineurin
participates in hyphal polarity development and spore size
dimorphism. Calcineurin is a promising drug target against
many fungal pathogens with dimorphic growth (Table 1).
Mucoralean hyphae are often heavy and have a bigger
diameter than in Ascomycota. Hyphae diameter and size
determine the efficacy of phagocytosis by macrophages. They
differ in cell wall composition as well, and they have less
glucan and more chitin compared with Ascomycota. This
change in biochemistry determines antifungal susceptibility/
resistance, because most antifungal drugs target either the cell
wall machinery or components. They are galactomannan-
negative; thus, serum tests based on this feature can differen-
tiate between Ascomycota and Zygomycota, but only to con-
firm the presence of Ascomycota and they provide no infor-
mation about the presence/absence of Zygomycota.
Zygomycota are resistant to most of the newer antifungals,
such as voriconazole and echinocandins, which are very effi-
cient against Candida and Aspergillus mycoses. The three
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orders of Zygomycota infecting humans have different
susceptibility/resistance patterns.
In vitro studies revealed the potential for biofilm formation
for R. oryzae, L. corymbifera, and R. pusillus, but not for
A. elegans [25]. The biofilm matrix is formed with glucos-
amine as the dominant dry component (Table 2).
Rhizopus oryzae is claimed to possess extraordinary ge-
nome plasticity owing to a whole genome duplication, which
resulted in an elevated number of genes, including those in-
volved in host–pathogen interactions [6, 26]. Currently, more
Zygomycota genomes have been sequenced, including
Lichtheimia hyalospora, Mucor circinelloides, Mortierella
elongata, Rhizopus microsporus, andConidiobolus coronatus,
which will enable comparative studies and accelerated screen-
ing of drug targets. Comparative analyses will facilitate the
identification of conserved components of the fungal cell
machinery. Based on the sole gene count and genome size
comparisons, it is clear that Rhizopus oryzae is an exception
regarding the number of genes in the whole collection of
currently sequencedZygomycetes, with the average gene num-
ber of 11 thousand genes. Table 3 lists the estimated genome
sizes and predicted gene numbers for Zygomycetes present in
the Joint Genome Institute (JGI) sequencing center database.
Systematics
Fungal systematics have been recently reorganized [27],
which resulted in temporary chaos in the nomenclature. A
revised taxonomic classification has been introduced for sev-
eral of the human and animal fungal pathogens that are also
part of the previous Zygomycota phylum [12–14]. These
changes in nomenclature should better reflect biological dif-
ferences among taxa. A reliable source of valid nomenclature
are the Index Fungorum and MycoBank. Zygomycota them-
selves do not currently constitute a valid taxon; instead, more
subphyla and orders are proposed.
Only 3 of the 13 orders of known Zygomycetes, namely the
Mucorales, the Mortierellales, and the Entomophthorales, har-
bor animal and human pathogens [28]. However, Mortierella
wolfii is a cattle pathogen, the documentation of human infec-
tions is scarce and no cases have been described since 2000.
Consequently, we will focus only on Mucorales and
Entomophthorales infections, called mucormycosis and
entomophthoromycosis respectively). Supplementary
Table S1 lists the Mucoromycotina, Mortierellomycotina,
and Entomophoromycotina that are involved in human infec-
tions with synonymic names and examples of case reports.
The mucoromycotina group contains most of the human path-
ogenic Zygomycota.
Some taxa have been recently revised, deemed to be species
complex and consequently divided into more taxa. Among
them, Apophysomyces spp. now account for four taxa with
differences in spore shape and ITS sequence levels [29]. Owing
to the introduction of separate taxa in 2010, most reports in the
literature refer toA. elegans. However, future work should refer
to the newest nomenclature. A similar pattern involves
Saksenaea vasiformis, which is now considered a species
Table 1 Summary of differentiating features among filamentous fungi
Character Ascomycota (e.g., Aspergillus) Zygomycota (e.g., Mucor)
Spores Hydrophobic spores (conidia), ascospores Dry and wet sporangiospores, zygospores
Hyphae Narrow (2–3 μm), septate, branching in different angles Broad (6–16 μm), coenocytic, orthogonal ramifications
Cell wall composition More glucan More chitin
Galactomannan present Galactomannan absent
Table 2 Summary of differentiating features of entomophthoromycosis
and mucormycosis
Feature Mucormycosis Entomophthoromycosis
Progression of the infection Rapidly invasive Local
Immune reaction Acute Chronic
Host immunity Compromised Competent
Localization Systemic Cutaneous, soft tissue
Lipase − +
Keratin degradation − +
Thermotolerance + −
Table 3 Currently sequenced Zygomycota genomes stored by the Joint
Genome Institute (JGI)
Organism and project name Genome
size
Number
of genes
Coemansia reversa NRRL 1564 v1.0 21,838,014 7,347
Umbelopsis ramanniana AG # v1.0 23,077,072 9,931
Conidiobolus coronatus NRRL28638 v1.0 39,903,661 10,635
Rhizopus microsporus var. microsporus v1.0 25,972,395 10,905
Mucor circinelloides CBS277.49 v2.0 36,587,022 11,719
Lichtheimia hyalospora v1.0 33,282,407 12,062
Gonapodya prolifera v1.0 48,794,828 13,902
Mortierella elongata v1.0 49,959,475 14,964
Phycomyces blakesleeanus NRRL1555 v2.0 53,939,167 16,528
Rhizopus oryzae 99-880 from Broad 46,087,117 17,467
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complex and in consequence was split into more taxa charac-
terized by spore shapes [30]. Among the most characteristic
pathogenicMucoralesRhizomucor variabiliswasmoved to the
Mucor genus based on molecular characteristic and renamed
Mucor irregularis [31]. Other taxa suspected to be species
complexwere confirmed as true species.Rhizopusmicrosporus
was revised as a single species and its varieties might be just
environmental variants. Importantly, foodborne, environmental
and clinical strains are indistinguishable [32]. This observation
supports the opportunistic character of mucormycoses
Host—fungus interaction
Key factors involved in fungal infections seem to be shared
among distantly related fungi pathogenic to different hosts
[24, 33].
The respiratory tract is the main entrance for fungi, among
them Zygomycetes. Inhaled aerosolized spores are removed
by the movements of ciliated epithelial cells. If some manage
to overcome this barrier the alveolar macrophages phagocy-
tose and destroy most spores. Healthy gastrointestinal tract
and skin are good barriers to Zygomycetes. It is not surprising
that most skin infections are a consequence of direct inocula-
tion due to severe trauma. Gastrointestinal infections are most
common in neonates, who have not yet developed proper
immune mechanisms.
The description of host pathogen interactions at a molecular
level shows differences in the mechanisms of aspergillosis and
mucormycosis, including host immune response and suscepti-
bility tomacrophage-induced hyphal damage [34]. Furthermore,
biological features of the causing agent determine the location
and progress of the infection, leading to a more localized infec-
tion in entomophthoromycosis and a progressive and potentially
disseminated infection in mucormycosis. Entomophthorales
specialized in cutin degradation exert keratinolytic enzymes; as
a consequence entomophthoromycoses are usually superficial
and gastrointestinal infections. In contrast to Entomophthorales,
human-infecting Mucorales are usually thermo-tolerant, which
makes them able to invade internal body parts and form a
chronic infection.
The interplay between pathogens and hosts varies among
fungal agents and the host condition. However, some general
trends can be drawn.Most of the mechanisms are known from
animal data; the latter should be considered with caution as the
inflammatory reaction is different in rodents and apes. The
role of the immune system in preventing and eliminating
fungal infections involves an inflammatory reaction. Inflam-
mation triggered by Zygomycota is usually less visible than in
aspergillosis. Ascomycota are recognized by both TRL2 and
TRL4 receptors, whereas Zygomycota are recognized solely
by TLR2 receptors [34]. There is another major difference
compared with aspergillosis regarding the involvement of T
lymphocytes. This is because innate immunity is indispens-
able in fighting a Zygomycota infection and the acquired
immunity involvement is not that pronounced. However,
Mucorales-specific T cells and NK cells can be found
both in patients and in healthy individuals. These find-
ings pave the way for potential diagnostic tests and
adoptive immunotherapy [35].
One of the most characteristic features of zygomycoses is
their occurrence in diabetic patients. Some aspects of the
interplay between the fungus and diabetic patients has been
revealed at a molecular level. During the infection R. oryzae
binds to GRP78 receptors [36, 37]. The expression of GRP78
receptor coding genes is affected by acidosis and by iron and
glucose levels, which are observed in diabetic patients (high
blood sugar levels and available iron). In such a scenario
R. oryzae become more resistant to neutrophils, which are
susceptible to low pH conditions. One taxon may produce
hyphae and spores of variable size. Phagocyte-induced dam-
age is related to target mass; bigger hyphae are harder to
phagocytose. Schmidt and colleagues [38] demonstrated that
both unstimulated and IL-2-prestimulated human NK cells
damage Rhizopus oryzae hyphae, but do not affect resting
conidia. They concluded that the damage of the fungus is
mediated, at least in part, by perforin. R. oryzae hyphae
decrease the secretion of immunoregulatory molecules by
NK cells, such as IFN-γ and RANTES (regulated on activa-
tion, normal T-cell expressed and secreted), indicating an
immunosuppressive effect of the fungus.
A study on the activity of human polymorphonuclear leu-
kocytes (PMNLs) against R. oryzae, R. microsporus, and
L. corymbifera revealed that interferon (IFN)-gamma and
granulocyte-macrophage colony-stimulating factor (GM-
CSF) augment the hyphal damage of all three zygomycetes.
Additionally, this effect was more pronounced against
L. corymbifera than against both Rhizopus species [39].
Genus-specific patterns could be drawn from pulled
data from multiple infections. It is currently known that
Cunninghammella is more aggressive than Lichtheimia in
diabetes patients [34]. It induces low TNFα levels and is
resistant to hyphae damage by macrophages. In rare cases
it can invade an immunocompetent host [40], which sug-
gests some of the specific properties of Cunninghammella
compared with other Mucorales. Cunninghammella infec-
tions have higher mortality rates than other, more com-
mon infections [8].
Epidemiology
Risk factors
There are several risk factors associated with opportunistic
fungal infections, among them zygomycoses. Diabetic
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ketoacidosis [8, 41], treatment with corticosteroids [42, 43],
deferoxamine in patients on dialysis [44], and immunosup-
pressive drugs [36] enhance susceptibility to developing
zygomycosis. Neutropenia [36, 45], malnutrition [46], cyto-
megalovirus infection [47], and extended wounds/burns [48,
49] are also predisposing conditions associated with
zygomycosis.
According to the main reviews by Roilides et al. [34] and
Ibrahim et al. [36] neutropenia, diabetes with blood hypergly-
cemia and low pH, Fe overload, corticosteroid therapy, and
direct inoculation as a result of trauma are the main risk
factors. Neutropenic patients are at increased risk, whereas
patients with AIDS are not. This is because T lymphocytes are
not key players in fighting against Zygomycota infection. The
phagocytes provide antifungal activity via oxidative metabo-
lites and defensins [36]. Immunosuppression leading to neu-
tropenia encountered in transplant recipients renders them
susceptible to zygomycosis. Corticosteroid therapy also influ-
ences neutrophils and their activity against fungi.
It has been found that [8] diabetic patients are exceptionally
susceptible to sinusitis infections. Diabetic patients have an
altered innate immunity with reduced chemotaxis of PMNLs,
impaired transmission through the vascular endothelium, and
reduced superoxide production [50, 51].
With regard to Fe overload, iron is indispensable for vital
life processes and as a such is a limiting factor. Pathogens
developed many traits to acquire iron from the host and
Zygomycetes are no an exception. Deferoxamine therapy is
suspected to facilitate Zygomycota infection by making iron
available.
Healthy skin provides an efficient barrier against
Mucorales; thus, skin trauma provides a risk of developing
mucormycosis [36]. This condition is favorable for fast-
growing opportunistic organisms. Contact with soil, food,
and water containing fungi can be detrimental to either burned
or severely wounded patients (Table 4).
Sources and routes of infection
Mucorales are ubiquitous in the environment. They may be
present in rotten organic debris (foods, fruits, vegetables,
seeds and nuts, plants). Sporangiospores are easily aerosolized
and dispersed in the air, which may be the source of infection
by inhalation of spores. However, the occurrence of
sporangiospores in indoor and outdoor air is less than that of
conidia of aspergilli and other molds.
There are three main routes of infection for Zygomycota.
The most common is via the respiratory system, i.e., the
sinuses and lungs. Wards where there are patients with neu-
tropenia and other risk factors for invasive fungal infection
should undergo air-conditioning monitoring, and plants,
which are potential sources of fungal growth and sporulation,
are not permitted there.
Published data describing the levels of zygomycete
sporangiospores in outdoor and indoor air in relation to sea-
sonal variation are scarce. It was suggested on the basis of two
articles from the Near East and analyses of the seasonal
presence of sporangiospores in outdoor air that mucormycosis
may occur seasonally at the end of the summer and in the fall,
when the weather is warm and humid [21].
The second route of infection is via direct inoculation of
fungal propagules into the human body. It can be iatrogenic or
commonly acquired. Nosocomial infection can be due to
contaminated medical devices, e.g., ostomy pouching sys-
tems, adhesive bandage, wooden tongue depressors, subcuta-
neous insulin infusion pump, peritoneal dialysis, intravascular
devices, or contamination during medical procedures, e.g.,
dental extraction and local anesthesia, intramuscular injection
of corticosteroids, vitamins and anticoagulants, nasal packing,
contamination of grafts, and during transplantation. Common-
ly acquired inoculation of zygomycota fungi may occur as a
result of traffic accidents, burns when the contaminated soil,
water, plant debris among others, comes into contact with
Table 4 Infection prevalence and its main features [8, 41, 52, 53]
Underlying disease/
condition
Percent of patients
with zygomycosis
The most common
form of infection
Mechanism and predisposing factors
Hematological malignancy 11–17 Pulmonary; disseminated Neutropenia, voriconazole prophylaxis
HSCT recipients 1, 2–5 Rhinocerebral; pulmonary Steroid prophylaxis for GvsH disease, neutropenia,
voriconazole prophylaxis
Diabetes mellitus 17–36 (74) Rhinocerebral, sinus Acidosis—increasing iron level acidosis and
hyperglycemia—has a negative impact on
neutrophil chemotaxins and phagocytic activity
Solid organ transplantation (0.6) 7–13, 23 Pulmonary, liver, and other transplant organ Transplant contamination
Deferoxamine therapy 1–6 Disseminated, pulmonary Increasing iron level
Burns, trauma in accident 13–20 Cutaneous, even 40 % of infections are
disseminated
Disruption of skin barrier (spore inoculation)
Malnourished patients 3 Gastrointestinal Digestion of the fungi
(Premature) neonates 3–21 Gastrointestinal
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injured skin and tissues. Infection can also occur through
insect bites. This route of infections is dominant in healthy
patients. The less common type of Zygomycota infection is
via the oral route [51].
Among nosocomial sources of infection there are reported
cases of contaminated biomedical devices and building con-
structions. In a review of 169 cases by Rammaert and col-
leagues [51] a variety of sources of infections are listed,
among them grafts, ostomy bags, adhesive bandages, water,
wooden tongue depressors, dental extraction and local anes-
thesia, blood glucose self-monitoring equipment, subcutane-
ous insulin infusion pump, peritoneal dialysis, intravascular
devices, intramuscular injection of corticosteroids and vita-
mins, and nasal packing. Neonatalogical, hematological,
transplantation and burn units should monitor their conditions
to ensure patients’ well-being.
Special focus should be directed toward donor-derived
filamentous fungal infections in transplant recipients [54],
which have a fatal outcome [51]. Environmental sources of
infection are dominant in healthy patients with a challenged
skin barrier—after trauma (car accident, burns), among them
soil/decaying organic matter [55] and water [56] should be
considered. Even plant pots in hospitals can be a source of
infection for immunosuppressed patients.
Prevalence
In the general population, zygomycosis is a very rare disease.
Orphanet (the Orpha number, i.e., the Orphanet identifier for
zygomycosis is 73263) classified it as a rare infectious dis-
ease; however, its prevalence is not known. There are several
estimations of the incidence of zygomycosis/mucormycosis,
showing some discrepancies. A more accurate assessment of
zygomycosis prevalence is currently not feasible owing to
incomplete identification and documentation. However, some
best practice approaches have been introduced, like the Work-
ing Group on Zygomycetes by the International Society for
Human and Animal Mycology (ISHAM). Rees and col-
leagues [57] estimated the incidence of mucormycosis to be
1.7 cases per million people per year, analyzing a population-
based study in the USA performed in the 1990s. A Spanish,
multicenter, population-based study, based on 6 diagnosed
cases of zygomycosis in Spain in 2005 [58], showed that the
incidence of zygomycosis was 0.43 out of 1,000,000 inhabi-
tants per year and 0.62 out of 100,000 hospital admissions.
That gives 430–1,700 cases per million per year worldwide.
However, Brown [59] estimated that more than 10,000 life-
threatening cases of mucormycosis occur worldwide per year,
with 30–90 % mortality rate within infected persons.
Postmortem prevalence evaluation shows that
mucormycosis is 10- to 50-fold less frequent than both can-
didiasis and aspergillosis, with a frequency of 1–5 cases per
10,000 autopsies [60–62]. Zygomycosis represents 8.3–13 %
of all fungal infections encountered at autopsy in high-risk
patients [52].
Males are more likely to be affected by zygomycosis than
women (58–68 % of cases [8, 63–65]). This fact can be
explained by the incidence of hematological malignancies
(HM) (and most cancers) being generally lower in women
than in men. The smaller number of cancers in women is a
well-documented phenomenon and could be in part the result
of a lower exposure to environmental and occupational risk
factors in women than in men [66, 67]. Omoti et al. [68]
reports that HM affects male (56 %) and adult (>15 years;
83 %) patients more often. However, Skiada et al. found that
there is no predilection as regards sex in cutaneous
zygomycosis, which affected generally healthy subjects [69].
In 2011, a large prospective multinational European study
based on 230 patients with zygomycosis showed that the most
common predisposing conditions were hematological malig-
nancies (44 %), trauma (17 %), DM (17 %), and hematopoi-
etic SCT (9 %) [65].
Hematological malignancies
Patients with hematological malignancies (HM) either with or
without hematopoietic stem cell transplantation (HSCT) con-
stitute the most commonly infected group. They account for
up to 44 % of all cases of zygomycosis [45, 52].
The retrospective cohort study was conducted in the hema-
tology wards of either tertiary care centers or university hos-
pitals located throughout Italy, between 1999 and 2003. Five
hundred and thirty-eight proven or probable invasive fungal
infections (IFI) in 11,802 patients with newly diagnosed he-
matology malignancies (AML, ALL, CML, CLL, NHL, HD,
and MM) were documented. The overall incidence of IFI was
4.6 %. Zygomycetes in this study occur in 1.2 out of 1,000
(0.12 %) HM patients (most frequently among AML and ALL
patients—0.3 %) with 64.3 % mortality rate (attributable
mortality rate 0.08 %). In this study zygomycetes were the
fourth most common agents of IFI following Aspergillus,
Candida, and Fusarium) [7].
In another study conducted in Southern Italy over
18 months, in 589 patients (475 adults and 114 pediatrics)
with newly diagnosed HM (AML, NHL, ALL, CLL,MM), 27
episodes of IFIs were documented [70]. The overall incidence
was 4.6 %. Of the 27 documented IFIs, 16 were caused by
yeasts (13 in adult patients and 3 in pediatric patients) and 11
by filamentous fungi (all in adult patients). A total of 11 mold
infections (40.7 %, 10 aspergillosis and 1 zygomycoses) were
reported only in adult patients (incidence 2.3 %). Occurrence
of zygomycosis was slightly higher than observed in the study
by Pagano et al. [7]—1.6 out of 1,000 vs 1.2 out of 1,000 HM
patients.
Neofytos and colleagues [71] performed a multicenter,
prospective, observational study to assess the epidemiological
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characters and outcomes of invasive fungal infection (IFI) in
hematopoietic stem cell transplant (HSCT) recipients in North
America. In this study were included 234 adult HSCT recip-
ients with a total of 250 cases of IFI. The most frequent was
invasive aspergillosis (59.2 %) followed by invasive candidi-
asis (24.8 %) and zygomycosis (7.2 %), and other molds
(6.8 %) [72]. In 178 autopsies of HSCT recipients (45.1 %)
infectious etiologies were found to contribute to the cause of
death. Fungal infections were found in 93 cases (23.5 %).
Among fungal infections caused by cultivable species the
most common was Aspergillus spp. (44.6 %) followed by
Candida (33.9 %), Zygomycota (7.1 %), and Pneumocystis
(7.1 %).
These data suggest that zygomycetes infection occurs in
1.7 % of patients with HSCT recipients (17 cases of
zygomycosis per 1,000 HSCT recipients).
Diabetes
Another risk factor is diabetes mellitus. Zygomycosis occurs
mainly in patients with uncontrolled diabetes, especially those
with ketoacidosis. In 2012 the WHO estimated the number of
diabetic patients to 220 million (current estimates from the
WHO Fact sheet no. 312, updated March 2013: 347 million
people worldwide have diabetes [73]). Zygomycoses are as-
sociated with DM in 17–36% of cases. If we take into account
estimates that worldwide there are 10,000 patients with
zygomycosis, which gives us 0.9-1.8 cases of zygomycosis
per 100,000 diabetic patients (approximately 0.0009–
0.0018 %).
The problem of zygomycosis in diabetic patients is associ-
ated with poverty and malnutrition, for example, in India
where uncontrolled DM was the most commonly found pre-
disposing factor in 74 % (n=131) of the 178 cases of
zygomycosis identified between 2000 and 2004 [74]. In con-
trast to France, where DM was associated with only 9 % of
531 cases of zygomycosis reported between 1997 and 2006
[63].
Solid organ transplantation
Zygomycoses have been reported from different organs such
as kidney, liver, heart and lung transplantations. Zygomycosis
was generally considered to be a rare complication in solid
organ transplant recipients [75]. Incidence of zygomycosis in
solid organ transplant recipients is estimated to range from 0.4
to 16 % depending on the procedure and geographical area
[63]. Themost recentmulticenter prospective study conducted
in the USA found that out of 16,457 transplant patients
12 had Mucorales infection (0.07 %); among organ re-
cipients in particular, Mucorales infection occurred as
follows: lung 2 out of 1,179 (0.17 %), liver 7 out of
4,361 (0.16 %), kidney 3 out of 8,494 (0.03 %); in the
pancreas (1,174), heart (1,159), and small bowel (69)
there were no zygomycosis infections [5].
Although zygomycoses are relatively rare they are charac-
terized by a severe course and high mortality rate. Early
diagnosis of the infection is still a challenge and the demand
for better diagnosis is growing with the increasing number of
reported cases. The latter is possibly caused by a species shift
resulting from the common prophylaxis of fungal infection
with azoles (fluconazole and voriconazole) in at-risk wards.
Zygomycota are not susceptible to azoles, except for
posaconazole.
Clinical manifestations
There are five main clinical manifestations of Zygomycosis
[52]: rhinocerebral, pulmonary, gastrointestinal, cutaneous,
and disseminated. Spellberg and colleagues listed six groups
of miscellaneous mucormycosis presentation in which they
included brain involvement without sinus infection, endocar-
ditis, pyelonephritis, bone infection, external otitis, etc. [53].
Among patients from the group at risk of zygomycosis, the
most common manifestation is rhino-(orbital)-cerebral (33–
49 %), followed by cutaneous (10–16 %), pulmonary (10–
11 %), disseminated (6–12 %), and gastrointestinal (2–11 %).
In immunocompetent/otherwise healthy patients the most rep-
resentative clinical form was the cutaneous/subcutaneous
form (42.5 % of patients), followed by the rhino-orbito-
cerebral (38 %) and genitourinary (8.5 %), disseminated,
and pulmonary infections [76].
Rhinocerebral mucormycosis
Rhinocerebral mucormycosis is the most common form
present in both neutropenic hematological and diabetic
patients. Initial symptoms are nonspecific, involving
headaches, altered mental status, fever, and eye syn-
drome, lacrimation, irritation, or periorbital anesthesia.
Unilateral vision disturbance and further changes involv-
ing ptosis, proptosis or loss of extraocular muscle func-
tion are signs of the progressing infection toward the
retro-orbital region or the central nervous system (CNS).
Necrotic black lesions on the hard palate, necrotic tur-
binates, and septum perforation should be carefully
inspected. The radiographic image of the infection can
be mimicked by bacterial and other fungal infections as
well as tumors. Scheckenbach and colleagues [77] re-
ported that initial CT scanning was not informative and
most manifestations were not specific; only histopathol-
ogy provided sufficient data to establish a reliable diag-
nosis. Proper management of the primary disease is
essential for a favorable outcome.
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Pulmonary mucormycosis
Pulmonary mucormycosis usually occurs in patients with
profound neutropenia, hematological malignancies, those on
corticosteroid therapy or those with diabetes. The symptoms
are not specific and involve fever, chest pain, and cough.
Neutropenia and coagulation dysfunctions make tissue collec-
tion inadvisable in some cases. Radiographic or CT scans
showing multiple (>10) nodules or pleural effusions can be a
sign of fungal infection. Although other mycoses, bacterial
infections or malignant invasions should be considered.
Gastrointestinal mucormycosis
Gastrointestinal mucormycosis is a very rare form of infec-
tion. It is associated with severe malnutrition and premature
birth. The infection is thought to be a consequence of the
ingestion of fungi. The symptoms including fever, pain,
vomiting, diarrhea, and constipation are nonspecific. The
infection may lead to ischemic infarction and ulceration. The
stomach, terminal ileum, and colon are the most common
sites; however, any part of the gastrointestinal tract can be
colonized. The diagnosis requires direct examination and
biopsy, and is often only performed at autopsy.
Cutaneous (skin) mucormycosis or entomophthoromycosis
Cutaneous infection can be either primary or secondary. A
primary infection develops in patients who have suffered
burns or other trauma. The infection is caused by direct
inoculation during an accident or can be nosocomial. The
disease manifestation involves erythema, pus, abscess forma-
tion, tissue swelling, necrosis, and pain in the infected area.
The skin appears red and indurated and the necrosis can be
observed as black eschars. The tissue necrosis can progress to
gangrenous cellulitis.
Cutaneous infection can be a secondary locus in patients
with disseminated infection from the respiratory tract. Cuta-
neous mucormycosis has been reported in diabetic patients.
Disseminated mucormycosis
This form of mucormycosis is the hardest to control and
constitutes the greatest threat to the patient. When two or more
noncontiguous organs are involved an infection can be con-
sidered disseminated. These often include lung and CNS
colonization, with the lung often being the primary infection
site. The involvement of the lung and skin is a sign of a higher
risk of CNS invasion as well. Since the disseminated form
often involves CNS colonization, the disease can manifest as
changes in the mental status. Other internal organs can be
secondarily invaded during colonization, among others the
spleen, liver, and even the heart, leading to pain in the infected
organ.
Pediatric cases
Zaoutis and colleagues consider that pediatric cases should be
treated as a separate category [78, 79]. There is limited infor-
mation about zygomycoses in children. Infection in children is
different: they tolerate more intensive treatment and GI tract
infections are fatal, being the third most common manifesta-
tions of zycomycoses in neonates.
Diagnosis of Zygomycota infections
Zygomycosis is still a challenge for diagnostics, especially
considering that early diagnosis is the best drug in
zygomycoses. The diagnosis relies on clinical findings, risk
factor analysis, histopathology, and culture samples inspec-
tion. The clinical signs vary with the form and stage of the
infection. In rhinocerebral zygmycosis, classic clinical fea-
tures include facial swelling, with ocular involvement. Pa-
tients often report facial and eye pain, proptosis, and visual
disturbances that are signs of the involvement orbital struc-
tures (muscles, nerves, and vessels). Black necrotic lesions
can also occur, for example, on the hard palate. Pulmonary
zygomycosis manifests with nonspecific symptoms such as
fever, cough, and dyspnea; when fungi invade vessels hemop-
tysis may also occur. Radiographic findings can be vague and
often overlap with other mold infections. The presentation of
pulmonary zygomycosis often resembles that of an invasive
aspergillosis in severely immunocompromised patients, for
example, HSCT recipients. Comparison of the CT imag-
ing features of pulmonary zygomycosis and invasive
pulmonary aspergillosis has shown that the presence of
multiple nodules (>10) and, to a lesser degree, the pres-
ence of pleural effusions, favored the presence of the
former diseases. Additionally, micronodules seen on the
initial CT scans were more commonly observed in pa-
tients with pulmonary zygomycosis [80]. Gastrointestinal
zygomycosis may occur in patients with severe malnu-
trition. The clinical picture mimics intra-abdominal ab-
scess. Unfortunately, the diagnosis is often made at au-
topsy. Differentiation with other fungal infection is very
important because Zygomycota are resistant to voriconazole,
a drug successfully used in the treatment of invasive
aspergillosis.
The diagnosis can be performed on several levels:
1. Identification of an invasive mold infection
2. Distinguishing between Ascomycota and Zygomycota
3. Species/genus identification
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Diagnostic imaging
Diagnostic imaging is useful in the early diagnosis of
rhinocerebral, non-enhanced paranasal sinuses or lung lesions.
This method allows the preliminary recognition of probable
Mucorales infection. Computed tomography (CT) has a
higher sensitivity and allows an earlier diagnosis than the
classical radiographic techniques. CT scans can reveal lesions
caused by angioinvasive fungi not visible on conventional
radiographs and before other clinical manifestations [81]. CT
gives the opportunity to show mucosal thickening and early
bone destruction. Lesions that could be revealed on lung CT
scans are nodules, halo signs, reverse halo signs, cavities,
wedge-shaped infiltrates, pleural effusions, and angioinvasion
of molds. These need to be confirmed by biopsy and molec-
ular or culture-based methods. The presence of pulmonary
infiltrates in neutropenic patients is already a sign of
angioinvasion, necrosis, thrombosis, hemorrhage, and edema.
These can be the first observable signs of angioinvasion and
systemic fungal infection. CT imaging of infected organs
often shows limited inflammation around hyphae compared
with Aspergillus. The observed lesions can change in the
course of infection, but are not specific enough to reliably
differentiate among causing agents like Aspergillus,
Scedosporium, Fusarium, Mucorales, and mixed infections.
The major disadvantage of using CT is the exposure of pa-
tients to a high dose of radiation. The radiation exposure
associated with CT scans limits their routine or serial usage.
Another imaging technique used in diagnostics is MRI.
This method is mandatory for assessing extension into the
cavernous sinus and identifying cerebral involvement. Le-
sions that can be revealed by MRI are orbital and intradural
expansion, cavernous sinus thrombosis, or thrombosis or an-
eurysm of the internal carotid artery.
Positron emission tomography (PET) has the highest sen-
sitivity among diagnostic imaging methods. This technique
can detect small infectious foci before the onset of the ana-
tomical abnormalities assessed by conventional radiology
tools. PET is not recommended for the evaluation of cerebral
involvement and in diabetic patients control of glycemia is
also required.
Preliminary diagnosis based on the above-described tech-
niques needs to be confirmed by biopsy and molecular or
culture-based methods.
Direct examination and culture-based methods
Direct examination can provide only limited information on
the causative agent, but in the absence of the quick diagnostic
test, biopsy with histopathological assessment remains a cru-
cial method in the diagnosis of zygomycosis. In tissue mate-
rials zygomycosis can be recognized by the presence of broad,
nonseptate hyphae, invading tissue and causing necrosis,
vascular invasion, and thrombosis. The hyphae of
Zygomycota branch at a right angle, as opposed to other fungi
such as Aspergillus, whose hyphae branch at a slight angle.
However, they can be easily overlooked in tissue samples
stained with nonfungal staining. Many infections are diag-
nosed definitively only at autopsy.
To diagnose mucormycosis different specimens are taken
that are adequate to the location of the ongoing process of
infection. For the rhinocerebral form the appropriate samples
are as follows: sinus aspirates, tissue specimens from the
affected area, and also scraping of the nasal mucosa. In the
case of pulmonary infection deep samples of tissues and
bronchoalveolar lavage (BAL) with flexible fiber optic bron-
choscopy can be obtained. Sputum testing is less sensitive,
especially in non-neutropenic patients. CT-guided biopsy can
also be performed in the case of negative BAL findings [82].
The biopsy of the lesion is necessary to establish the
diagnosis of cutaneous mucormycosis. The biopsy specimen
should be taken from the center of the lesion and include
subcutaneous fat, because molds frequently invade blood
vessels of the dermis and subcutis, resulting in an ischemic
cone at the skin surface [83]. Impression smears from the
wound edges may also help with the diagnosis [69].
Culture is useful for identification of etiological agents and
antifungal drug susceptibility testing. Mucorales are fast
growing molds; thus, 24-h incubation on fungal media like
Sabouraud agar and malt extract agar at 25–37 °C usually
suffices for colony formation. A positive culture in a patient
with no clinical symptoms should be interpreted with caution
because of the possibility of environmental contamination.
Besides the classic morphological identification of molds
there are some metabolic markers that are important for
species/genus identification, such as the ability to grow within
certain temperature ranges and assimilation of different com-
pounds as a sole carbon source.
Human pathogenic Mucorales differ with regard to carbon
source utilization patterns [84], which could be used for
species identification, either directly in culture-dependent as-
says or for the development of metabolite-based approaches.
There are limited data on species differences in pathology/
treatment owing to the very recent establishment of some of
the aforementioned new taxa. Differential carbon source us-
age was reported for Apophysomyceswith negative results for
assimilation of D-galactose and other sugars [29] and positive
for the members of six other genera of pathogenic
Zygomycota, i.e., Cunninghamella, Lichtheimia, Mucor,
Rhizopus, Rhizomucor, and Syncephalastrum [84]. Such dif-
ferences might be used to develop identification tests.
Species identification can be confirmed by molecular
methods based on the sequencing of a standard PCR product
obtained with universal fungal ITS primers on DNA extracted
from a culture, enabling reliable order/species level identifi-
cation of the infecting fungus. In laboratories equipped with
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reference libraries techniques such as MALDI-TOF might
also be possible from culture samples.
Culture-independent methods: molecular diagnosis
Currently, there are no circulating antigen detection tests
available. The promising 1,3 beta-D-glucan tests are common-
ly found to be negative in Mucorales. A double
galactomannan and 1,3 beta-D-glucan test can be of help in
excluding invasive aspergillosis or a double infection by
Aspergillus and Mucorales. PCR-based tests of blood samples
are not yet available. Consequently biological samples of the
infected sites should be collected for histopathology and cul-
ture. Invasive diagnostic biopsy of infected tissue in sinus and
lung infections should be performed. Blood and cerebrospinal
fluid are usually culture-negative.
Culture-independent molecular techniques are being devel-
oped: some are complex and laborious [85] and others require
sophisticated equipment and reference datasets. Zhao and
colleagues describe an assay based on a combination of
broad-range PCR amplification and reverse line blot hybridi-
zation (PCR/RLB) that enabled them to identify fungi from
tissue samples in 7 h [85] with high specificity (no false-
positives) and false-negatives solely for fungi not included
in the reference. Additionally, their method works for concen-
trations of 1.8×10−3 ng/μl of genomic DNA.
More specific and sensitive molecular markers and second-
ary metabolite identification methods are still being
developed.
MALDI-TOF diagnostics are currently based on reference
datasets and require cultivation; however, a development of
serum-based profiles is expected in the near future.
Treatment
According to the largest meta-analysis performed by Roden
and colleagues [8], lack of treatment had a fatal outcome, with
only 3 % survival. A double treatment consisting of antifungal
therapy combined with surgical intervention was most suc-
cessful, leading to the survival of 70 % of patients.
Early diagnosis is the key factor for a successful outcome
[8]. This is followed by surgical debridement and antifungal
therapy. Necrotic tissue resulting from disease progression
may require repeated excision as it prevents antifungal agent
penetration [45]. Amphotericin B is the main drug used in the
treatment of mucormycosis, entomophthoromycosis and
mortierellomycosis. High therapeutic dosage should be
achieved as soon as possible. Lipid formulations tend to be
better tolerated, limiting the nephrotoxicity [86]. Currently, no
other drug displays comparable activity against all three
groups of fungi. The main antifungal drugs belong to five
different groups: echinocandins, azoles, polyenes,
allylamines, and pyrimidine analogs. The echinocandins
(caspofungin, micafungin, and anidulafungin) inhibit the syn-
thesis of 1,3-β-D-glucan, an essential component of the fungal
cell wall. Azoles (fluconazole, hexaconazole, isavuconazole,
itraconazole, posaconazole, ravuconazole, voriconazole) are
lanosterol 14 alpha-demethylase inhibitors. Polyenes bind
ergosterol, a cell membrane component (amphotericin B, nys-
tatin, and natamycin). Allylamines inhibit squalene
monooxygenase; among them only terbinafine is used against
fungi. Themain antifungal pyrimidine analog and thymidylate
synthase inhibitor is flucytosine.
An evaluation of amphotericin B, ketoconazole, flucona-
zole, intraconazole, voriconazole, posaconazole, caspofungin,
and flucytosine activity against most of the human pathogenic
Mucorales: Rhizopus sp. R. arrhizus, R. microsporus var.
rhizopodiformis, R. microsporus var. micorsporus, Mucor
sp. M. circinelloides group, Rhizomucor sp., Absidia sp.
Abs id ia corymbi fe ra , and Cunninghamel la sp .
Apophysomyces elegans revealed that posaconazole is the
second most promising drug [6]. A recent report from the
3rd European Conference on Infections in Leukemia (ECIL
3) provides a detailed guideline regarding the diagnosis and
treatment and lists as yet unanswered questions [45].
Amphotericin B
Amphotericin B deoxycholate was introduced more than
50 years ago and become the gold standard of therapy for
invasive mycoses [86, 87]. It has a broad spectrum activity
against most fungal agents and serves as a reference in
searches for novel antifungal drugs. The administration of
AMB causes severe side effects, among them high nephro-
toxicity, which leads to the development of less nephrotoxic
lipid formulations. The latter can be administered in higher
doses than the native drug. Comparative trials are performed
between the more common liposomal amphotericin B
(LAmB) and amphotericin B colloidal dispersion (ABCD),
which is less frequently studied.
Posaconazole
Posaconazole is an exception among azoles, which display
either moderate or no activity against most of the strains
tested. Mucorales are in general susceptible to amphotericin
B, but display variable response to posaconazole. A recent
report from the SEIFEM and FUNGISCOPE [7, 88] registries
evaluated the outcome of combined lipid formulation of
amphotericin B (LAmpB) posaconazole (POS) therapy of
invasive mucormycosis in 32 patients [88]. This evaluation
was essential because of the limited number of cases in
previous clinical reports and inconclusive previous studies
that reported synergistic effects in vitro and no improvement
relative to LAmpB monotherapy in mouse models. Pagano
and colleagues conclude that a combined therapy should be
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considered in severe cases of invasive mucormycosis. Addi-
tionally, it is recommended to consider prophylaxis with
posaconazole in at-risk groups. It is a broad spectrum drug
that is protective against Zygomycota and Fusarium,
Penicillium, Histoplasma, Blastomyces, Coccidioides,
Paracoccidioides, Sporotrix, chromoblastomycosis, myceto-
ma, phaeohyphomycosis, including Scedosporium
apiospermum and Exophiala, Alternaria, and Bipolaris spp.
[89]. Among other things it has been used for the successful
treatment of Cunninghamella elegans infection [90]. Further-
more, it is the most active drug in A. elegans treatment, has
lower MIC than AmpB [91]. Saksenaeaceae (Apophysomyces
and Saksenaea) seem to be most responsive to the antifungals
posaconazole, itraconazole, and terbinafine [92], but not
AmpB.
Voriconazole
Previous exposure of Rhizopus oryzae to voriconazole en-
hances virulence in animal models [93, 94]. It is discussed
whether the co-occurrence of voriconazole application for
antifungal prophylaxis in immunocompromised patients with
the frequency of zygomycosis is of a causal nature [4]
Caspofungin
Reports of caspofungin treatment show discrepancies between
in vitro and in vivo results. It is claimed that caspofungin
facilitates the development of some zygomycoses in a similar
manner to voriconazole and is associated with a worse out-
come [65]. On the other hand, caspofungin shows synergy
with AmpB in a mouse model [95]. There is a repeatedly
confirmed paradox of caspofungin efficacy decreasing to con-
trol level when administered in higher doses in murine models
[96].
Terbinafine
Recently, terbinafine has been successfully administered in
patients with mucormycosis [83, 97, 98]. The drug has been
primarily used against dermatophytes, but further usage in-
cluded Candida and Zygomycota. Terbinafine was the most
active compound (among amphotericin B, voriconazole,
posaconazole, itraconazole, ravuconazole, terbinafine, and
caspofungin) in an in vitro study of antifungal activity against
five strains of Cunninghamella bertholletiae and four of
Cunninghamella echinulata [99]. However, it is intriguing
why in vivo studies did not include this compound. Neverthe-
less, the compound was successfully applied against
Basidiobolus ranarum in a combination with itraconazole in
a rhino-facial infection [100].
Combined antifungal therapy
Spellberg with colleagues [101] formulated three recommen-
dations to introduce phase III clinical trials with combined
therapy:
1. Improved survival in relevant animal models of
mucormycosis
2. Available retrospective data that are concordant with the
preclinical models both for efficacy and safety
3. Involvement of already approved therapeutic agents
The consortium proposed three potentially effective therapeu-
tic combinations: lipid polyene and echinocandin, lipid
polyene/posaconazole and deferasirox, and lipid polyene and
posaconazole/isavuconazole. The aforementioned (L)AmpB
and posaconazole combination was the most commonly used
combined therapy in patients with hematological diseases
reported from the SEIFEM and FUNGISCOPE registries. In
the aforementioned studies LAmB+POS was administered
when antifungal monotherapy failed to produce a response.
These patients were treated with a monotherapy for a median
time of 18 days before LAmB+POS combined therapy was
introduced. A robust and consistent assessment of drug effi-
cacy and the influence of combined therapy on patients’
outcome is limited by such factors as the limited number of
cases, the lack of regular therapeutic drug monitoring, the
uncontrolled impact of surgical debridement, and the burden
of underlying diseases.
The concluding remark from the analyses of Pagano and
colleagues [88] was that a combined antifungal treatment with
LAmB+POS may be considered in patients with very aggres-
sive forms of IM. This is the only drug combination that is
consistently recommended by independent authorities. How-
ever, other combinations have been described as well.
In vitro studies as well as animal studies suggested a
synergistic effect of deferasirox in combination with LAmB
[102]. However, a randomized, double-blinded, placebo-
controlled trial showed that patients with mucormycosis treat-
ed with deferasirox with LAmB had a higher mortality rate at
90 days than patients treated with LAmB with placebo. Au-
thors emphasized that population imbalances in this small
phase II study limit possible generalizations. Spellberg and
co-authors concluded that although no obvious toxicities were
identified, deferasirox cannot be recommended as part of an
initial combination regimen for the treatment of
mucormycosis [103].
From the theoretical point of view echinocandins should be
active against Mucorales: R. oryzae produces the target en-
zyme for echinocandins [103]. In vitro studies show higher
MICs for this group of drugs [104]. In a mouse model of
disseminated mucormycosis a combination of caspofungin
with ABLC [95] and LAmB with either micafungin or
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anidulafungin [105] markedly and synergistically improved
survival compared with either monotherapy or placebo. Reed
and colleagues conducted a retrospective study concluding
that either ABLC or LAmB combined with CASP improved
survival for patients with rhinocerebral mucormycosis com-
pared with polyene monotherapy [106]. Micafungin was also
successfully combined with LAmpB; however, systematic
trials are lacking [107]. This effect was previously observed
in an animal model of disseminated mucormycosis [105]. All
these data “provide strong a rationale for a phase III, random-
ized double-blinded, placebo-controlled study to determine
whether lipid polyene plus echinocandins are indeed superior
to lipid polyene plus placebo therapy” [103].
Alternative therapy
Iron chelators and hyperbaric oxygen
Both iron chelators (deferasirox and deferiprone) and hyper-
baric oxygen have been used in some cases. However, they are
not well documented enough to get positive recommendations
from ECIL 3 [45].
Immunotherapy and immunostimulation
Adoptive immunotherapy with T cells after stimulation with
cellular extracts of fungi may form the basis for future clinical
trials. Simultaneous stimulation with Aspergillus fumigatus,
Candida albicans, and Rhizopus oryzae extracts enables a
generation of multi-specific T cells that recognize a wide
variety of taxa [108]. These in vitro and in vivo results may
represent a hope for allogeneic hematopoietic stem cell trans-
plantation recipients with invasive fungal infection. However,
there is no sufficient clinical evidence to formulate recom-
mendations to use this approach in systemic zygomycosis
[109].
The ECIL 3 suggests that the growth factors granulocyte
colony-stimulating factor (G-CSF), granulocyte macrophage
colony-stimulating factor (GM-CSF), and interferon-γ
(IFN-γ) should be used in neutropenic patients with
mucormycosis. Their administration in other patients needs
to be studied further.
Final remarks
The constantly growing number of patients susceptible to
fungal infections emphasizes the critical need for better treat-
ment and diagnostics. These can be developed based on
rigorous meta-analyses of well-described case reports with
proper taxon identification, treatment, and outcome
description.
Acknowledgements This research was supported by National Science
Centre grant 2012/07/D/NZ2/04286 to A.M.
Conflict of interest The authors declare that they have no conflict of
interest.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
References
1. Krings M, Taylor TN, Dotzler N (2013) Fossil evidence of the
zygomycetous fungi. Persoonia 30(1):1–10. doi:10.3767/
003158513X664819
2. Almyroudis NG, Nikolaos G, Nikolaos G, Sutton DA, Fothergill
AW, Rinaldi MG, Kusne S (2007) In vitro susceptibilities of 217
clinical isolates of zygomycetes to conventional and new antifungal
agents. Antimicrob Agents Chemother 51(7):2587–2590. doi:10.
1128/AAC.00452-07
3. Farina C, Marchesi G, Passera M, Diliberto C, Russello G (2012)
Comparative study of the in vitro activity of various antifungal
drugs against Scedosporium spp. in aerobic and hyperbaric atmo-
sphere versus normal atmosphere. J Mycol Med 22(2):142–148.
doi:10.1016/j.mycmed.2012.01.001
4. Pongas GN, Lewis RE, Samonis G, Kontoyiannis DP (2009)
Voriconazole-associated zygomycosis: a significant consequence
of evolving antifungal prophylaxis and immunosuppression prac-
tices? Clin Microbiol Infect 15 [Suppl 5]:93–97. doi:10.1111/j.
1469-0691.2009.02988.x
5. Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ,
Walsh TJ, Pappas PG (2010) Prospective surveillance for invasive
fungal infections in hematopoietic stem cell transplant recipients,
2001-2006: overview of the Transplant-Associated Infection
Surveillance Network (TRANSNET) Database. Clin Infect Dis
50(8):1091–1100. doi:10.1086/651263
6. Lewis RE, Lortholary O, Spellberg B, Roilides E, Kontoyiannis DP,
Walsh TJ (2012) How does antifungal pharmacology differ for
mucormycosis versus aspergillosis? Clin Infect Dis 54 [Suppl 1]:
S67–S72. doi:10.1093/cid/cir884
7. Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B,
Nosari A (2006) The epidemiology of fungal infections in patients
with hematologic malignancies: the SEIFEM-2004 study.
Haematologica 91(8):1068–1075. Retrieved from http://www.
ncbi.nlm.nih.gov/pubmed/16885047
8. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova
TA, Schaufele RL, Walsh TJ (2005) Epidemiology and outcome of
zygomycosis: a review of 929 reported cases. Clin Infect Dis 41(5):
634–653. doi:10.1086/432579
9. Vikram HR, Smilack JD, Leighton JA, Crowell MD, De Petris G
(2012) Emergence of gastrointestinal basidiobolomycosis in the
United States, with a review of worldwide cases. Clin Infect Dis
54(12):1685–1691. Retrieved from http://www.ncbi.nlm.nih.gov/
pubmed/22441651
10. Baradkar VP,Mathur M, Taklikar S, Rathi M, Kumar S (2008) Fatal
rhino-orbito-cerebral infection caused by Saksenaea vasiformis in
an immunocompetent individual: first case report from India. Indian
J Med Microbiol 26(4):385–387. Retrieved from http://www.ncbi.
nlm.nih.gov/pubmed/18974499
11. Thomas AJ, Shah S, Mathews MS, Chacko N (2008)
Apophysomyces elegans—renal mucormycosis in a healthy host:
1284 Eur J Clin Microbiol Infect Dis (2014) 33:1273–1287
a case report from south India. Indian J Med Microbiol 26(3):269–
271, Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/
18695332
12. Hoffmann K, Pawłowska J, Walther G, Wrzosek M, de Hoog GS,
Benny GL, Voigt K (2013) The family structure of theMucorales: a
synoptic revision based on comprehensive multigene-genealogies.
Persoonia 30(1):57–76. doi:10.3767/003158513X666259
13. Gryganskyi AP, Humber RA, Smith ME, Hodge K, Huang B, Voigt
K , Vi l g a l y s R ( 2 0 1 3 ) P h y l o g e n e t i c l i n e a g e s i n
Entomophthoromycota. Persoonia 30(1):94–105. doi:10.3767/
003158513X666330
14. Wagner L, Stielow B, Hoffmann K, Petkovits T, Papp T, Vágvölgyi
C, Voigt K (2013) A comprehensive molecular phylogeny of the
Mortierellales (Mortierellomycotina) based on nuclear ribosomal
DNA. Persoonia 30(1):77–93. doi:10.3767/003158513X666268
15. Ainsworth GC (2008) Ainsworth & Bisby’s dictionary of the fungi.
Retrieved from http://www.google.pl/books?hl=pl&lr=&id=IFD4_
VFRDdUC&pgis=1
16. LuX-L, NajafzadehMJ, Dolatabadi S, RanY-P, Gerrits van den Ende
AHG, Shen Y-N, de Hoog GS (2013) Taxonomy and epidemiology
of Mucor irregularis, agent of chronic cutaneous mucormycosis.
Persoonia 30(1):48–56. doi:10.3767/003158513X665539
17. Segvić Klarić M, Pepeljnjak S (2006) A year-round
aeromycological study in Zagreb area, Croatia. Ann Agric
Environ Med 13(1):55–64. Retrieved from http://www.ncbi.nlm.
nih.gov/pubmed/16841873
18. Vesper SJ, Wymer LJ, Meklin T, Varma M, Stott R, Richardson M,
Haugland RA (2005) Comparison of populations of mould species
in homes in the UK and USA using mould-specific quantitative
PCR. Lett Appl Microbiol 41(4):367–373. doi:10.1111/j.1472-
765X.2005.01764.x
19. Ejdys E (2007) Fungi isolated in school buildings. Acta Mycol
42(2):245–254
20. Gniadek A, Macura AB (2007) Intensive care unit environment
contamination with fungi. Adv Med Sci 52:283–287. Retrieved
from http://www.ncbi.nlm.nih.gov/pubmed/18217434
21. El-Herte RI (2012) Mucormycosis: a review on environmental
fungal spores and seasonal variation of human disease. Adv Infect
Dis 2(3):76–81. doi:10.4236/aid.2012.23012
22. Khan ZU, Ahmad S, Brazda A, Chandy R (2009) Mucor
circinelloides as a cause of invasive maxillofacial zygomycosis:
an emerging dimorphic pathogen with reduced susceptibility to
posaconazole. J Clin Microbiol 47(4):1244–1248. doi:10.1128/
JCM.02030-08
23. Desjardins CA, Champion MD, Holder JW, Muszewska A,
Goldberg J, Bailão AM, Cuomo CA (2011) Comparative genomic
a n a l y s i s o f h um a n f u n g a l p a t h o g e n s c a u s i n g
paracoccidioidomycosis. PLoS Genet 7(10), e1002345. doi:10.
1371/journal.pgen.1002345
24. Lee SC, Li A, Calo S, Heitman J (2013) Calcineurin plays key roles
in the dimorphic transition and virulence of the human pathogenic
zygomycete mucor circinelloides. PLoS Pathog 9(9):e1003625. doi:
10.1371/journal.ppat.1003625
25. Singh R, Shivaprakash MR, Chakrabarti A (2011) Biofilm formation
by zygomycetes: quantification, structure and matrix composition.
Microbiology 157(Pt 9):2611–2618. doi:10.1099/mic.0.048504-0
26. Ma L-J, Ibrahim AS, Skory C, Grabherr MG, Burger G, Butler M,
Wickes BL (2009) Genomic analysis of the basal lineage fungus
Rhizopus oryzae reveals a whole-genome duplication. PLoS Genet
5(7):e1000549. doi:10.1371/journal.pgen.1000549
27. Hibbett DS, Taylor JW (2013) Fungal systematics: is a new age of
enlightenment at hand? Nat Rev Microbiol 11(2):129–133. doi:10.
1038/nrmicro2963
28. Voigt K, Vaas L, Stielow B, de Hoog GS (2013) The zygomycetes
in a phylogenetic perspective. Persoonia 30(1):1–4. doi:10.3767/
003158513X666277
29. Alvarez E, Garcia-Hermoso D, Sutton DA, Cano JF, Stchigel AM,
Hoinard D, Guarro J (2010) Molecular phylogeny and proposal of
two new species of the emerging pathogenic fungus Saksenaea. J
Clin Microbiol 48(12):4410–4416. doi:10.1128/JCM.01646-10
30. Alvarez E, Stchigel AM, Cano J, Sutton DA, Fothergill AW,
Chander J, Guarro J (2010) Molecular phylogenetic diversity of
the emerging mucoralean fungus Apophysomyces: Proposal of
three new species. Rev Iberoam Micol 27(2):80–89. doi:10.1016/
j.riam.2010.01.006
31. Alvarez E, Cano J, Stchigel AM, Sutton DA, Fothergill AW, Salas
V, Guarro J (2011) Two new species of Mucor from clinical sam-
ples. Med Mycol 49(1):62–72. doi:10.3109/13693786.2010.
499521
32. Dolatabadi S, Walther G, Gerrits van den Ende AHG, Hoog GS
(2013) Diversity and delimitation of Rhizopus microsporus. Fungal
Divers. doi:10.1007/s13225-013-0229-6
33. Gauthier GM, Keller NP (2013) Crossover fungal pathogens: the
biology and pathogenesis of fungi capable of crossing kingdoms to
infect plants and humans. Fungal Genet Biol. doi:10.1016/j.fgb.2013.
08.016
34. Roilides E, Kontoyiannis DP, Walsh TJ (2012) Host defenses
against zygomycetes. Clin Infect Dis 54 [Suppl 1]:S61–S66. doi:
10.1093/cid/cir869
35. Ibrahim AS, Kontoyiannis DP (2013) Update on mucormycosis
pathogenesis. Curr Opin Infect Dis. doi:10.1097/QCO.
0000000000000008
36. Ibrahim AS, Spellberg B, Walsh TJ, Kontoyiannis DP (2012)
Pathogenesis of mucormycosis. Clin Infect Dis Off Publ Infect
Dis Soc Am 54 [Suppl 1]:S16–S22. doi:10.1093/cid/cir865
37. Liu M, Spellberg B, Phan QT, Fu Y, Fu Y, Lee AS, Ibrahim AS
(2010) The endothelial cell receptor GRP78 is required for
mucormycosis pathogenesis in diabetic mice. J Clin Invest 120(6):
1914–1924. doi:10.1172/JCI42164
38. Schmidt S, Tramsen L, Perkhofer S, Lass-Flörl C, Hanisch M,
Röger F, Lehrnbecher T (2013) Rhizopus oryzae hyphae are dam-
aged by human natural killer (NK) cells, but suppress NK cell
mediated immunity. Immunobiology 218(7):939–944. doi:10.
1016/j.imbio.2012.10.013
39. Gil-Lamaignere C, Simitsopoulou M, Roilides E, Maloukou A,
Winn RM, Walsh TJ (2005) Interferon- gamma and granulocyte-
macrophage colony-stimulating factor augment the activity of poly-
morphonuclear leukocytes against medically important
zygomycetes. J Infect Dis 191(7):1180–1187. doi:10.1086/428503
40. Gupta R, Goel N, Gupta A, Gupta KB, Chaudhary U, Sood S (2011)
A rare fungal infiltration of lungs in a healthy young girl. Case Rep
Pulmonol 2011:917089. doi:10.1155/2011/917089
41. Rammaert B, Lanternier F, Poirée S, Kania R, Lortholary O (2012)
Diabetes and mucormycosis: a complex interplay. Diabetes Metab
38(3):193–204. doi:10.1016/j.diabet.2012.01.002
4 2 . P r abhu RM, Pa t e l R (2004 ) Muco rmyco s i s a nd
entomophthoramycosis: a review of the clinical manifestations, di-
agnosis and treatment. Clin Microbiol Infect 10 [Suppl 1]:31–47.
Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/14748801
43. Zaki SM, Elkholy IM, Elkady NA, Abdel-Ghany K (2013)
Mucormycosis in Cairo, Egypt: review of 10 reported cases. Med
Mycol. doi:10.3109/13693786.2013.809629
44. Chayakulkeeree M, Ghannoum MA, Perfect JR (2006)
Zygomycosis: the re-emerging fungal infection. Eur J Clin
Microbiol Infect Dis 25(4):215–229. doi:10.1007/s10096-006-
0107-1
45. Skiada A, Lanternier F, Groll AHA, Pagano L, Zimmerli S,
Herbrecht R, Petrikkos GL (2013) Diagnosis and treatment of
mucormycosis in patients with hematological malignancies: guide-
lines from the 3rd European Conference on Infections in Leukemia
(ECIL 3). Haematologica 98(4):492–504. doi:10.3324/haematol.
2012.065110
Eur J Clin Microbiol Infect Dis (2014) 33:1273–1287 1285
46. Sun H-YH, Singh N (2011) Mucormycosis: its contemporary face
and management strategies. Lancet Infect Dis 11(4):301–311. doi:
10.1016/S1473-3099(10)70316-9
47. Mysorekar VV, Rao SG (2008) Cytomegalovirus pneumonia with
pulmonary mucormycosis. Indian J Pathol Microbiol 51(2):294–295.
Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/18603715
48. Andresen D, Donaldson A, Choo L, Knox A, Klaassen M, Ursic C,
Konecny P (2005) Multifocal cutaneous mucormycosis complicating
polymicrobial wound infections in a tsunami survivor from Sri Lanka.
Lancet 365(9462):876–878. doi:10.1016/S0140-6736(05)71046-1
49. Ledgard JP, van Hal S, Greenwood JE (2008) Primary cutaneous
zygomycosis in a burns patient: a review. J Burn Care Res 29(2):
286–290. doi:10.1097/BCR.0b013e31816673b1
50. Peleg AY, Weerarathna T, McCarthy JS, Davis TME (2007)
Common infections in diabetes: pathogenesis, management and
relationship to glycaemic control. Diabetes/Metab Res Rev 23(1):
3–13. doi:10.1002/dmrr.682
51. Rammaert B, Lanternier F, Zahar J-R, Dannaoui E, BougnouxM-E,
Lecuit M, Lortholary O (2012) Healthcare-associated
mucormycosis. Clin Infect Dis 54 [Suppl 1]:S44–S54. doi:10.
1093/cid/cir867
52. Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ,
Kontoyiannis DP (2012) Epidemiology and clinical manifestations
of mucormycosis. Clin Infect Dis 54 [Suppl 1]:S23–S34. doi:10.
1093/cid/cir866
53. Spellberg B, Edwards J, Ibrahim A (2005) Novel perspectives on
mucormycosis: pathophysiology, presentation, and management.
Clin Microbiol Rev 18(3):556–569. doi:10.1128/CMR.18.3.556-
569.2005
54. Bakr A, Wafa E, Fouda A, Elagroudy A, Gheith O, Sobh M,
Ghoneim M (2008) Successful treatment of mucormycosis in a
renal allograft recipient. Clin Exp Nephrol 12(3):207–210. doi:10.
1007/s10157-008-0028-7
55. Austin CL, Finley PJ, Mikkelson DR, Tibbs B (2013)
Mucormycosis: a rare fungal infection in tornado victims. J Burn
Care Res. doi:10.1097/BCR.0b013e318299d4bb
56. Ribeiro NFF, Heath CH, Kierath J, Rea S, Duncan-Smith M, Wood
FM (2010) Burn wounds infected by contaminated water: case
reports, review of the literature and recommendations for treatment.
Burns 36(1):9–22. doi:10.1016/j.burns.2009.03.002
57. Rees JR, Pinner RW, Hajjeh RA, Brandt ME, Reingold AL (1998)
The epidemiological features of invasive mycotic infections in the
San Francisco Bay area, 1992–1993: results of population-based
laboratory active surveillance. Clin Infect Dis 27(5):1138–1147.
Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/9827260
58. Torres-Narbona M, Guinea J, Martínez-Alarcón J, Muñoz P, Gadea
I, Bouza E (2007) Impact of zygomycosis on microbiology work-
load: a survey study in Spain. J Clin Microbiol 45(6):2051–2053.
doi:10.1128/JCM.02473-06
59. Brown GD, Denning DW, Gow NAR, Levitz SM, Netea MG,
White TC (2012) Hidden killers: human fungal infections. Sci
Transl Med 4(165):165rv13. doi:10.1126/scitranslmed.3004404
60. Hotchi M, Okada M, Nasu T (1980) Present state of fungal infec-
tions in autopsy cases in Japan. Am J Clin Pathol 74(4):410–416.
Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/7424823
61. Tietz HJ, Brehmer D, Jänisch W, Martin H (1998) [Incidence of
endomycoses in the autopsy material of the Berlin Charité
Hospital]. Mycoses 41 [Suppl 2]:81–85. Retrieved from http://
www.ncbi.nlm.nih.gov/pubmed/10085694
62. Yanagisawa E, Friedman S, Kundargi RS, Smith HW (1977)
Rhinocerebral phycomycosis. Laryngoscope 87(8):1319–1335.
doi:10.1288/00005537-197708000-00012
63. Lanternier F, Dannaoui E, Morizot G, Elie C, Garcia-Hermoso D,
Huerre M, Lortholary O (2012) A global analysis of mucormycosis
in France: the RetroZygo Study (2005–2007). Clin Infect Dis 54
[Suppl 1]:S35–S43. doi:10.1093/cid/cir880
64. Rüping MJGT, Heinz WJ, Kindo AJ, Rickerts V, Lass-Flörl C,
Beisel C, Cornely OA (2010) Forty-one recent cases of invasive
zygomycosis from a global clinical registry. J Antimicrob
Chemother 65(2):296–302. doi:10.1093/jac/dkp430
65. Skiada A, Pagano L, Groll A, Zimmerli S, Dupont B, Lagrou K,
Petrikkos G (2011) Zygomycosis in Europe: analysis of 230 cases
accrued by the registry of the European Confederation of Medical
Mycology (ECMM) Working Group on Zygomycosis between
2005 and 2007. Clin Microbiol Infect 17(12):1859–1867. doi:10.
1111/j.1469-0691.2010.03456.x
66. Cook MB, Dawsey SM, Freedman ND, Inskip PD, Wichner SM,
Quraishi SM, McGlynn KA (2009) Sex disparities in cancer inci-
dence by period and age. Cancer Epidemiol Biomarkers Prev 18(4):
1174–1182. doi:10.1158/1055-9965.EPI-08-1118
67. Sant M, Allemani C, Tereanu C, De Angelis R, Capocaccia R,
Visser O, Berrino F (2010) Incidence of hematologic malignancies
in Europe by morphologic subtype: results of the HAEMACARE
project. Blood 116(19):3724–3734. doi:10.1182/blood-2010-05-
282632
68. Omoti C, Nwannadi A, Obieche J, Olu-Eddo A (2012) The
Epidemiological features of lymphoid malignancies in Benin City,
Nigeria: a 15 years study. Pan Afr Med J. doi:10.4314/pamj.v11i1
69. Skiada A Rigopoulos D, Larios G (2012) Global epidemiology of
cutaneous zygomycosis. Clin Dermatol 30(6):628–632. Retrieved
from http://www.sciencedirect.com/science/article/pii/
S0738081X12000405
70. Montagna MT, De Giglio O, Napoli C, Lovero G, Caggiano G,
Delia M, Specchia G (2012) Invasive fungal infections in patients
with hematologic malignancies (aurora project): lights and shadows
during 18-months surveillance. Int J Mol Sci 13(1):774–787. doi:
10.3390/ijms13010774
71. Neofytos D, Horn D, Anaissie E, Steinbach W, Olyaei A, Fishman
J, Marr K (2009) Epidemiology and outcome of invasive fungal
infection in adult hematopoietic stem cell transplant recipients:
analysis of Multicenter Prospective Antifungal Therapy (PATH)
Alliance registry. Clin Infect Dis 48(3):265–273. doi:10.1086/
595846
72. Alsharif M, Cameron SEH, Young J-AH, Savik K, Henriksen JC,
Gulbahce HE, Pambuccian SE (2009) Time trends in fungal infec-
tions as a cause of death in hematopoietic stem cell transplant
recipients: an autopsy study. Am J Clin Pathol 132(5):746–755.
doi:10.1309/AJCPV9DC4HGPANKR
73. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek
CJ, Ezzati M (2011) National, regional, and global trends in fasting
plasma glucose and diabetes prevalence since 1980: systematic
analysis of health examination surveys and epidemiological studies
with 370 country-years and 2.7 million participants. Lancet
378(9785):31–40. doi:10.1016/S0140-6736(11)60679-X
74. Chakrabarti A, Das A, Mandal J, Shivaprakash MR, George VK,
Tarai B, Sakhuja V (2006) The rising trend of invasive zygomycosis
in patients with uncontrolled diabetes mellitus. Med Mycol 44(4):
335–342. doi:10.1080/13693780500464930
75. Almyroudis NG, Sutton DA, Linden P, Rinaldi MG, Fung J, Kusne
S (2006) Zygomycosis in solid organ transplant recipients in a
tertiary transplant center and review of the literature. Am J
Transplant 6(10):2365–2374. doi:10.1111/j.1600-6143.2006.
01496.x
76. Mignogna M, Fortuna G, Leuci S (2011) Mucormycosis in immu-
nocompetent patients: a case-series of patients with maxillary sinus
involvement and a critical review of the literature. J Infect 15(8):
e533–e540. Retrieved from http://www.sciencedirect.com/science/
article/pii/S1201971211000488
77. Scheckenbach K, Cornely O, Hoffmann TK, Engers R, Bier H,
Chaker A, Wagenmann M (2010) Emerging therapeutic options in
fulminant invasive rhinocerebral mucormycosis. Auris Nasus
Larynx 37(3):322–328. doi:10.1016/j.anl.2009.09.001
1286 Eur J Clin Microbiol Infect Dis (2014) 33:1273–1287
78. Prasad PA, Vaughan AM, Zaoutis TE (2012) Trends in
zygomycosis in children. Mycoses 55(4):352–356. doi:10.1111/j.
1439-0507.2011.02124.x
79. Roilides E, Zaoutis TE, Katragkou A, Benjamin DK, Walsh TJ
(2009) Zygomycosis in neonates: an uncommon but life-
threatening infection. Am J Perinatol 26(8):565–573. doi:10.1055/
s-0029-1220775
80. Chamilos G, Marom EM, Lewis RE, Lionakis MS, Kontoyiannis
DP (2005) Predictors of pulmonary zygomycosis versus invasive
pulmonary aspergillosis in patients with cancer. Clin Infect Dis
41(1):60–66. doi:10.1086/430710
81. Walsh TJ, Gamaletsou MN, McGinnis MR, Hayden RT,
Kontoyiannis DP (2012) Early clinical and laboratory diagnosis
of invasive pulmonary, extrapulmonary, and disseminated
mucormycosis (zygomycosis). Clin Infect Dis 54 [Suppl 1]:S55–
S60. doi:10.1093/cid/cir868
82. Lass-Flörl C, Resch G, Nachbaur D, Mayr A, Gastl G, Auberger J,
Freund MC (2007) The value of computed tomography-guided
percutaneous lung biopsy for diagnosis of invasive fungal infection
in immunocompromised patients. Clin Infect Dis 45(7):e101–e104.
doi:10.1086/521245
83. Keller KA (2012) Therapeutic review: terbinafine. J Exot Pet Med
21(2):181–185. doi:10.1053/j.jepm.2012.02.007
84. Schwarz P, Lortholary O, Dromer F, Dannaoui E (2007) Carbon
assimilation profiles as a tool for identification of zygomycetes. J
Clin Microbiol 45(5):1433–1439. doi:10.1128/JCM.02219-06
85. Zhao Z, Li L, Wan Z, Chen W, Liu H, Li R (2011) Simultaneous
detection and identification of Aspergillus and mucorales species in
tissues collected from patients with fungal rhinosinusitis. J Clin
Microbiol 49(4):1501–1507. doi: 10.1128/JCM.02262-10
86. Antoniadou A, Dupont B (2005) Lipid formulations of
amphotericin B: where are we today? J Mycol Med 15(4):230–
238. doi:10.1016/j.mycmed.2005.06.005
87. Klepser M (2011) The value of amphotericin B in the treatment of
invasive fungal infections. J Crit Care 26(2):225.e1–225.e10. doi:
10.1016/j.jcrc.2010.08.005
88. Pagano L, Cornely O, Busca A, Caira M, Cesaro S, Gasbarrino C,
Vehreschild MJGT (2013) Combined antifungal approach for the
treatment of invasive mucormycosis in patients with hematological
diseases: a report from the SEIFEM and FUNGISCOPE registries.
Haematologica. doi:10.3324/haematol.2012.083063
89. Scheinfeld N (2007) A review of the new antifungals: posaconazole,
micafungin, and anidulafungin. J Drugs Dermatol 6(12):1249–1251.
Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/18189069
90. Garbino J,Myers C, Ambrosioni J, Gumy-Pause F (2010) Report of
a successful treatment of pulmonary Cunninghamella bertholletiae
infection with liposomal amphotericin and posaconazole in a child
with GvHD and review of the literature. J Pediatr Hematol Oncol
32(2):85–87. doi:10.1097/MPH.0b013e3181c2bdce
91. Chakrabarti A, Shivaprakash MR, Curfs-Breuker I, Baghela A,
Klaassen CH, Meis JF (2010) Apophysomyces elegans: epidemiol-
ogy, amplified fragment length polymorphism typing, and in vitro
antifungal susceptibility pattern. J Clin Microbiol 48(12):4580–
4585. doi:10.1128/JCM.01420-10
92. Hospenthal DR, Chung KK, Lairet K, Thompson EH, Guarro J,
Renz EM, Sutton DA (2011) Saksenaea erythrospora infection
following combat trauma. J Clin Microbiol 49(10):3707–3709.
doi:10.1128/JCM.05095-11
93. Lamaris GA, Ben-Ami R, Lewis RE, Chamilos G, Samonis G,
Kontoyiannis DP (2009) Increased virulence of Zygomycetes or-
ganisms following exposure to voriconazole: a study involving fly
andmurine models of zygomycosis. J Infect Dis 199(9):1399–1406.
doi:10.1086/597615
94. Lewis RE, Liao G, Wang W, Prince RA, Kontoyiannis DP (2011)
Voriconazole pre-exposure selects for breakthrough mucormycosis
in a mixed model of Aspergillus fumigatus-Rhizopus oryzae
pulmonary infection. Virulence 2(4):348–355. Retrieved from
http://www.ncbi.nlm.nih.gov/pubmed/21788730
95. Spellberg B, Fu Y, Edwards JE, Ibrahim AS (2005) Combination
therapy with amphotericin B lipid complex and caspofungin acetate
of disseminated zygomycosis in diabetic ketoacidotic mice.
Antimicrob Agents Chemother 49(2):830–832. doi:10.1128/AAC.
49.2.830-832.2005
96. Lewis RE, Leventakos K, Liao G, Kontoyiannis DP (2011)
Efficacy of caspofungin in neutropenic and corticosteroid-
immunosuppressed murine models of invasive pulmonary
mucormycosis. Antimicrob Agents Chemother 55(7):3584–
3587. doi:10.1128/AAC.01812-10
97. Pérez A (1999) Terbinafine: broad new spectrum of indications in
several subcutaneous and systemic and parasitic diseases. Mycoses
42(Suppl 2):111–114, Retrieved from http://www.ncbi.nlm.nih.gov/
pubmed/10865916
98. Revankar SG, Nailor MD, Sobel JD (2008) Use of terbinafine in
rare and refractory mycoses. Future Microbiol 3(1):9–17. doi:10.
2217/17460913.3.1.9
99. Pastor FJ, Ruíz-CendoyaM, Pujol I, Mayayo E, Sutton DA, Guarro
J (2010) In vitro and in vivo antifungal susceptibilities of the
Mucoralean fungus Cunninghamella. Antimicrob Agents
Chemother 54(11):4550–4555. doi:10.1128/AAC.00786-10
100. Goyal A, Gupta N, Das S, Jain S (2010) Basidiobolomycosis of the
nose and face: a case report and a mini-review of unusual cases of
basidiobolomycosis. Mycopathologia 170(3):165–168. doi:10.
1007/s11046-010-9310-9
101. Spellberg B, Ibrahim AS, Chin-Hong PV, Kontoyiannis DP, Morris
MI, Perfect JR, Brass EP (2012) The Deferasirox-AmBisome
Therapy for Mucormycosis (DEFEATMucor) study: a randomized,
double-blinded, placebo-controlled trial. J Antimicrob Chemother
67(3):715–722. doi:10.1093/jac/dkr375
102. Ibrahim AS, Bowman JC, Avanessian V, Brown K, Spellberg B,
Edwards JE, Douglas CM (2005) Caspofungin inhibits Rhizopus
oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured
by quantitative PCR, and improves survival at a low but not a high
dose during murine disseminated zygomycosis. Antimicrob Agents
Chemother 49(2):721–727. doi:10.1128/AAC.49.2.721-727.2005
103. Spellberg B, Ibrahim A, Roilides E, Lewis RE, Lortholary O,
Petrikkos G, Walsh TJ (2012) Combination therapy for
mucormycosis: why, what, and how? Clin Infect Dis 54 [Suppl 1]:
S73–S78. doi:10.1093/cid/cir885
104. Vitale RG, de Hoog GS, Schwarz P, Dannaoui E, Deng S,
Machouart M, Walther G (2012) Antifungal susceptibility and
phylogeny of opportunistic members of the order mucorales. J
Clin Microbiol 50(1):66–75. doi:10.1128/JCM.06133-11
105. Ibrahim AS, Gebremariam T, Fu Y, Edwards JE, Spellberg B (2008)
Combination echinocandin-polyene treatment of murine
mucormycosis. Antimicrob Agents Chemother 52(4):1556–1558.
doi:10.1128/AAC.01458-07
106. Reed C, Bryant R, Ibrahim AS, Edwards J, Filler SG, Goldberg R,
Spellberg B (2008) Combination polyene-caspofungin treatment of
rhino-orbital-cerebral mucormycosis. Clin Infect Dis 47(3):364–
371. doi:10.1086/589857
107. Ogawa T, Takezawa K, Tojima I, Shibayama M, Kouzaki H, Ishida
M, Okabe H, Shimizu T (2012) Successful treatment of rhino-
orbital mucormycosis by a new combination therapy with liposomal
amphotericin B and micafungin. Auris Nasus Larynx 39(2):224–
228. doi: 10.1016/j.anl.2011.03.006
108. Tramsen L, Schmidt S, Boenig H, Latgé J-P, Lass-Flörl C, Roeger F,
Lehrnbecher T (2013) Clinical-scale generation of multi-specific anti-
fungal T cells targeting Candida, Aspergillus and mucormycetes.
Cytotherapy 15(3):344–351. doi:10.1016/j.jcyt.2012.11.014
109. Antachopoulos C, Katragkou A, Roilides E (2012) Immunotherapy
against invasive mold infections. Immunotherapy 4(1):107–120.
doi:10.2217/imt.11.159
Eur J Clin Microbiol Infect Dis (2014) 33:1273–1287 1287
